More data isn't automatically better if it's the wrong data
From a mechanistic perspective, GLP-1RAs like exenatide notably decreased the percentage of Th17 cells while promoting the proliferation of Tregs by influencing the signaling cascade encompassing phosphatidylinositol 3-kinase (PI3K), protein kinase B (AKT), along with forkhead box O1 (FoxO1) [147]
Early results have been highly promising, and it is anticipated that Retatrutide could receive FDA approval in 2024 or 2025, depending on how the trials progress
Coverage changes can disrupt care and make them drop treatment or pay out of pocket, even up to $1,000 a month
It received FDA approval for its excellent biocompatibility, biodegradability, biosafety, and versatility and has become one of the most successful polymers in the biomedical field[85]